Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer
4/28/2014 8:58:18 AM
KVISTGAARD, Denmark, April 28, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by